HS
CERE

HighVista Strategies’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

HighVista Strategies’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-97,200
Closed -$3.97M – 173
2024
Q2 		$3.97M Hold
97,200
– – 1.45% 13
2024
Q1 		$4.11M Hold
97,200
– – 1.47% 14
2023
Q4 		$4.12M Buy
97,200
+72,313
+291% +$2.08M 1.5% 12
2023
Q3 		$543K Buy
+24,887
New +$623K 0.25% 99
2022
Q4 		– Sell
-23,611
Closed -$667K – 130
2022
Q3 		$667K Sell
23,611
-4,839
-17% -$144K 0.38% 71
2022
Q2 		$752K Buy
+28,450
New +$808K 0.45% 49

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

HighVista Strategies's CERE Position: Q3 2024 in Review

HighVista Strategies sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 97,200 shares — an estimated $3.97M sold.

HighVista Strategies first reported a position in CERE in Q2 2022 and held it in 6 quarters. The position peaked at $4.12M in Q4 2023. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • HighVista Strategies reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • HighVista Strategies sold 97,200 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $3.97M.
  • HighVista Strategies first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q2 2022 and held it in 6 quarters.
  • HighVista Strategies's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $4.12M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on HighVista Strategies's 13F filing for Q3 2024, filed 14 Nov 2024.